ClinicalTrials.Veeva

Menu

Extension Study of Biostate in Subjects With Von Willebrand Disease

CSL Behring logo

CSL Behring

Status and phase

Completed
Phase 3

Conditions

Von Willebrand Disease

Treatments

Biological: Biostate

Study type

Interventional

Funder types

Industry

Identifiers

NCT01224808
2009-017301-11 (EudraCT Number)
CSLCT-BIO-09-64
1498 (Other Identifier)

Details and patient eligibility

About

The aim of the Von Willebrand Disease (VWD) therapy is to treat and prevent bleeding episodes due to abnormal platelet adhesion and abnormal blood coagulation as a result of low or abnormal Von Willebrand Factor (VWF) and/or Factor VIII (FVIII) levels. The long-term efficacy and safety of a VWF/FVIII concentrate, Biostate, will be investigated in children, adolescents, and adults with VWD in whom treatment with a VWF product is required for prophylactic therapy, haemostatic control during surgery, or control of a non-surgical, spontaneous, or traumatic bleeding event.

Enrollment

20 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Have completed Study CSLCT-BIO-08-52 (Assessment of Efficacy and Safety of Biostate in Paediatric Subjects with Von Willebrand Disease) or Study CSLCT-BIO-08-54 (Assessment of Efficacy and Safety of Biostate in Adolescent or Adult Subjects with Von Willebrand Disease).
  • The subject and/or his/her legal guardian understand(s) the nature of the study and has/have given written informed consent to participate in the study and is/are willing to comply with the protocol.

Exclusion criteria

  • Early discontinuation of a subject from the main studies CSLCT-BIO-08-52 or CSLCT-BIO-08-54.
  • Mental condition rendering the subject (or the subject's legal guardian) unable to understand the nature, scope and possible consequences of the study.
  • Any condition that is likely to interfere with evaluation of the IMP or satisfactory conduct of the study.
  • Are not willing and/or not able to comply with the study requirements.
  • Employee at the study site, or spouse/partner or relative of the Investigator or Subinvestigators.
  • Female subjects of childbearing potential either not using, or not willing to use, a medically reliable method of contraception for the entire duration of the study, or not sexually abstinent for the entire duration of the study, or not surgically sterile.
  • Intention to become pregnant during the course of the study.
  • Pregnancy, or nursing mother.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

20 participants in 1 patient group

Experimental
Experimental group
Treatment:
Biological: Biostate

Trial contacts and locations

6

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems